Incretin Atlas › Trials › STEP 2
STEP 2
Semaglutide · t2d
Design
- Molecule(s)
- Semaglutide
- Population
- t2d
- Official title
- Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity
- Sponsor
- Novo Nordisk A/S
- Phase
- 3
- Registry status
- completed · 2018-06 → 2020-03
- Participants
- 1210
- Duration
- 68 weeks
- Registry
- NCT03552757
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| semaglutide 2.4 mg | t2d | 68 | 1210 | −10.6 % vs −3.1 % Δ −7.5 pp | −9.6 % vs −3.4 % Δ −6.2 pp | −1.6 vs −0.4 | 6.2 vs 3.5 | 11.6 vs 13.9 | 33.7 vs 9.2 | 21.8 vs 2.7 | 9.9 vs 9.2 | −3.9 vs −0.5 | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (9)
- semaglutide 2.4 mg · weight_eff · Results, paragraph 2 (Figure 2B)
The change for the trial product estimand was −10·6% (SE 0·4) for semaglutide 2·4 mg versus −3·1% (SE 0·4) for placebo
- semaglutide 2.4 mg · weight_tp · Table 2
Bodyweight change from baseline to week 68 (SE), % −9·64% (0·4) −6·99% (0·4) −3·42% (0·4)
- semaglutide 2.4 mg · ae_dc · Table 3
Adverse events leading to trial product discontinuation 25 (6·2%) 34 6·4
- semaglutide 2.4 mg · disc_any · Figure 1 (trial profile)
47 discontinued treatment prematurely*
- semaglutide 2.4 mg · nausea · Table 3
Nausea 136 (33·7%) 249 46·7
- semaglutide 2.4 mg · vomiting · Table 3
Vomiting 88 (21·8%) 188 35·3
- semaglutide 2.4 mg · sae · Table 3
Serious adverse events 40 (9·9%) 71 13·3
- semaglutide 2.4 mg · hba1c · Table 2
Change from baseline to week 68 (SE) −1·6% (0·1) −1·5% (0·1) −0·4% (0·1)
- semaglutide 2.4 mg · sbp · Table 2
Change from baseline to week 68 (SE) −3·9 (0·7) −2·9 (0·9) –0·5 (0·8)
Primary sources
- Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-984. PMID: 33667417.
- Novo Nordisk A/S. Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity and Type 2 Diabetes (STEP 2). ClinicalTrials.gov identifier NCT03552757. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT03552757
How to cite this page
Medical Adviser's Group. Incretin Atlas: STEP 2. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/step-2/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.